Budesonide Inhalation Suspension
- First Online:
- 227 Downloads
Budesonide, a topically active corticosteroid, has a broad spectrum of clinically significant local anti-inflammatory effects in patients with inflammatory lung diseases including persistent asthma.
In infants and young children with persistent asthma, day- and night-time symptom scores, and the number of days in which β2-agonist bronchodilators were required, were significantly lower during randomised, double-blind treatment with budesonide inhalation suspension 0.5 to 2 mg/day than placebo in 3 multicentre trials. Significantly fewer children discontinued therapy with budesonide inhalation suspension than with placebo because of worsening asthma symptoms in a study that included children who were receiving inhaled corticosteroids at baseline.
Recent evidence indicates that budesonide inhalation suspension is significantly more effective than nebulised sodium cromoglycate in improving control of asthma in young children with persistent asthma.
At a dosage of 2 mg/day, budesonide inhalation suspension significantly reduced the number of asthma exacerbations and requirements for systemic corticosteroids in preschool children with severe persistent asthma. In children with acute asthma or wheezing, the preparation was as effective as, or more effective than oral prednisolone in improving symptoms.
In children with croup, single 2 or 4mg dosages of budesonide inhalation suspension were significantly more effective than placebo and as effective as oral dexamethasone 0.6 mg/kg or nebulised L-epinephrine (adrenaline) 4mg in alleviating croup symptoms and preventing or reducing the duration of hospitalisation.
Early initiation of therapy with budesonide inhalation suspension 1 mg/day appears to reduce the need for mechanical ventilation and decrease overall corticosteroid usage in preterm very low birthweight infants at risk for chronic lung disease.
In adults with persistent asthma, budesonide inhalation suspension ≤8 mg/day has been compared with inhaled budesonide 1.6 mg/day and fluticasone propionate 2 mg/day administered by metered dose inhaler. Greater improvements in asthma control occurred in patients during treatment with budesonide inhalation suspension than with budesonide via metered dose inhaler, whereas fluticasone propionate produced greater increases in morning peak expiratory flow rates than nebulised budesonide. Several small studies suggest that the preparation has an oral corticosteroid-sparing effect in adults with persistent asthma and that it may be as effective as oral corticosteroids during acute exacerbations of asthma or chronic obstructive pulmonary disease.
The frequency of adverse events was similar in children receiving budesonide inhalation suspension 0.25 to 2 mg/day or placebo in 12-week studies. During treatment with budesonide inhalation suspension 0.5 to 1 mg/day in 3 nonblind 52-week studies, growth velocity in children was generally unaffected; however, a small but statistically significant decrease in growth velocity was detected in children who were not using inhaled corticosteroids prior to the introduction of budesonide inhalation suspension. Hypothalamic-pituitary-adrenal axis function was not affected by short (12 weeks) or long (52 weeks) term treatment with nebulised budesonide.
In conclusion, budesonide inhalation suspension is the most widely available nebulised corticosteroid, and in the US is the only inhaled corticosteroid indicated in children aged ≥1 year with persistent asthma. The preparation is suitable for use in infants, children and adults with persistent asthma and in infants and children with croup.
Budesonide is a topically active corticosteroid with anti-inflammatory properties. In patients with asthma, the drug suppresses the number of inflammatory cells in the lungs, inhibits synthesis and release of cytokines, reduces bronchial hyper-responsiveness to a variety of substances and attenuates both the early and late asthmatic response.
A single 4mg dose of nebulised budesonide inhalation suspension did not perturb serum cortisol levels in healthy adult volunteers. Similarly, budesonide inhalation suspension 1 to 4 mg/day had no significant effect on plasma markers of systemic corticosteroid activity in bone, blood or adrenal tissue in adult patients with asthma. In contrast, significant dose-related suppression of eosinophil counts and both osteocalcin and morning plasma cortisol levels occurred during treatment with oral prednisolone 5 to 20 mg/day in this randomised, double-blind, crossover study.
No pharmacodynamic studies have been conducted in children with asthma during treatment with budesonide inhalation suspension. However, when administered as a dry powder, inhaled budesonide produced significant improvement in markers of inflammation in inhaled corticosteroid-naive children that were correlated with reductions in use of as-needed β-agonist bronchodilators and improvements in asthma symptom scores and pulmonary function tests.
The mass median aerodynamic diameter of the droplets in budesonide inhalation suspension is ≈3 to 5μm when the preparation is administered via jet nebuliser with compressor. In adults, the lung deposition of budesonide from the nebulised suspension was ≈15% of the nominal dose when delivered by 3 commonly used jet nebulisers. The systemic bioavailability of budesonide was 6% after a single 1000μg dose of budesonide inhalation suspension in children aged 3 to 6 years with persistent asthma; in adults, the systemic bioavailability of budesonide was 13%. The volume of distribution at steady state, terminal elimination half-life and clearance of budesonide were 3 L/kg, 2.3 hours and 32.2 L/h, respectively, in children and 2.7 L/kg, 2.3 hours and 80.4 L/h, respectively, in adults.
Budesonide inhalation suspension has been evaluated in infants and young children aged 6 months to 8 years with symptomatic persistent asthma in 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group trials. After 12 weeks of treatment, daytime and night-time asthma symptom scores, the primary efficacy variables in these studies, were significantly lower among infants and children treated with budesonide inhalation suspension 0.5 to 2 mg/day than among those receiving placebo. The number of days during which β2-agonist bronchodilators were required for breakthrough asthma symptoms was also reduced significantly in children treated with budesonide compared with placebo. In 1 study, in which all children were receiving inhaled corticosteroids prior to enrolment, the proportion of children who discontinued therapy because of worsening of asthma symptoms was significantly greater in placebo than budesonide 0.5 to 2 mg/day recipients.
Budesonide inhalation suspension 1mg twice daily significantly reduced the number of asthma exacerbations and the requirements for systemic corticosteroids in preschool children with severe persistent asthma in 2 small, randomised, double-blind studies.
Recent data indicate that budesonide inhalation suspension is significantly more effective than nebulised sodium cromoglycate in improving control of asthma symptoms in young children with persistent asthma.
In randomised trials, nebulised budesonide was as effective as or more effective than oral prednisolone in improving symptoms in children with acute asthma or wheezing.
Budesonide inhalation suspension is an effective and well tolerated alternative to systemic corticosteroids in children with mild to severe croup. The formulation, given as a 2 or 4mg single dose, was more effective than placebo and as effective as oral dexamethasone 0.6 mg/kg in alleviating croup symptoms and reducing the duration of hospital stay in several studies. In 1 small study, budesonide inhalation suspension was as effective as nebulised L-epinephrine 4mg in young children with moderately severe croup.
Several published studies with budesonide have failed to demonstrate a beneficial effect on the symptoms of acute bronchiolitis or the prevention of post-bronchiolitic wheezing during the 6-month to 1-year period after treatment. Two-year follow-up results from arecently published prospective, nonblind study suggests that administration of budesonide inhalation suspension during and for 2 months after respiratory syncytial virus-bronchiolitis may reduce the development of subsequent respiratory symptoms. Double-blind studies with long term follow-up (≥2 years) are needed to confirm these results.
In very low birthweight infants (median birthweight 805g) born prior to 30 weeks of gestation, nebulised budesonide 0.5mg twice daily for 14 days significantly reduced overall requirement for corticosteroids and facilitated discontinuation of mechanical ventilation compared with placebo. There was, however, no significant difference in supplemental oxygen requirements at 28 days of age between the 2 groups in this randomised, double-blind study.
Improvements in asthma control were significantly greater in patients with asthma during treatment with budesonide inhalation suspension 2 or 8 mg/day than inhaled budesonide 1.6 mg/day administered by a metered dose inhaler plus spacer device in a randomised, double-blind, crossover study. Greater improvements in morning and evening peak expiratory flow and greater reductions in as-needed β2-agonist use occurred in patients during treatment with budesonide 8 mg/day than budesonide via metered dose inhaler. Greater increases in evening peak expiratory flow rates were documented during treatment with a lower dosage of budesonide inhalation suspension (2 mg/day) than budesonide via metered dose inhaler in this 4-week crossover study.
High dosages of fluticasone propionate via metered dose inhaler provided greater improvements in asthma control than budesonide inhalation suspension 2 or 4 mg/day in a randomised, nonblind, multicentre, crossover trial. Morning peak expiratory flow rates increased by a significantly greater extent after switching from nebulised budesonide 2 or 4 mg/day to inhaled fluticasone propionate 2 mg/day. There were, however, no differences in the number of 24-hour symptom-free intervals during 4 weeks of treatment with fluticasone propionate or budesonide inhalation suspension. Systemic effects on hypothalamic-pituitary-adrenal axis function were not quantified in this study.
Several small studies suggest that budesonide inhalation suspension has an oral corticosteroid-sparing effect in some adults with persistent asthma. The mean dosage of prednisolone was reduced by 59% (from 12.6 mg/day) in 55% of patients after 12 weeks’ treatment with budesonide inhalation suspension 2 mg/day in a noncomparative study.
Nebulised budesonide may be as effective as oral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). In a randomised, double-blind, multicentre study, forced expiratory volume in 1 second increased by a similar amount in 188 hospitalised patients with acute exacerbations of COPD during 3 days’ treatment with budesonide inhalation suspension 2mg every 6 hours or oral prednisolone 30mg every 12 hours. Both active treatments were significantly more effective than placebo in increasing post-bronchodilator forced expiratory volume in 1 second.
Budesonide inhalation suspension was generally well tolerated in clinical studies in infants and children. The frequency of adverse events was similar in children receiving budesonide inhalation suspension 0.25 to 2 mg/day or placebo in 12-week studies. Growth velocity was generally unaffected in children who had prior exposure to inhaled corticosteroids during 3 nonblind 52-week studies in which patients received budesonide inhalation suspension 0.5 to 1 mg/day or standard asthma care. Children with persistent asthma who were not using inhaled corticosteroids prior to receiving budesonide inhalation suspension experienced a small but significant decrease in growth velocity compared with those who received standard asthma care. There was no evidence of hypothalamic-pituitary-adrenal axis suppression after 12 weeks’ double-blind and 52 weeks’ nonblind treatment with budesonide inhalation suspension.
In adults with oral and inhaled corticosteroid-dependent asthma, reduced dosages of oral prednisolone after the introduction of budesonide inhalation suspension for 12 weeks resulted in the resolution of systemic adverse events in 24% of patients, and reduced the overall incidence of purpura, moon face, skin thinning and weight gain.
Dosage and Administration
In the US, budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children aged 12 months to 8 years. In children receiving treatment with inhaled bronchodilators and/or inhaled corticosteroids, the recommended initial dosage is 0.5 mg/day. In those receiving oral corticosteroids, a higher initial dosage (1 mg/day) is recommended. The maximum recommended dosage in children is 0.5 mg/day in those previously receiving bronchodilators and 1 mg/day in those who were receiving inhaled or oral corticosteroids.
In the UK and elsewhere, budesonide inhalation suspension is indicated for use in children and adults with asthma. The recommended dosage in infants and children aged 3 months to 12 years with asthma is 1 to 2 mg/day when starting treatment, during an asthma exacerbation or during withdrawal of oral corticosteroids; maintenance doses are typically 50% lower than the starting dose. In adults and children aged >12 years, the starting dosage of budesonide inhalation suspension is 2 to 4 mg/day, although higher doses may be necessary in very severe cases of asthma.
In children with croup the usual dose of budesonide inhalation suspension is 2mg given as a single inhalation or as two 1mg doses 30 minutes apart.
- 1.Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma-United States, 1960–1995. MMWR Morb Mortal Wkly Rep 1998; 47(SS-1): 1–28Google Scholar
- 19.Durand M, Joseph M, Baker AS. Infections of the upper respiratory tract. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998: 183Google Scholar
- 30.Brownlee KG. A rationale for the use of nebulized steroids in children. Eur Resp Rev 1997; 7(44): 177–9Google Scholar
- 43.Thorsson L, Thunnisen F, Corn S, et al. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo [abstract]. Am J Respir Crit Care Med 1998; 157: A404Google Scholar
- 44.Miller-Larson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623–30Google Scholar
- 45.Wieslander E, Delander E-L, Sjödin K, et al. Fatty acid conjugation of budesonide in normal human bronchial epithelial cells [abstract]. Am J Respir Crit Care Med 1998; 157(3): A402Google Scholar
- 46.Wieslander E, Delander E-L, Järkelid L, et al. Reversible fatty acid conjugation of budesonide results in prolonged anti-inflammatory activity in vitro as compared to fluticasone propionate [abstract]. Am J Respir Crit Care Med 1997; 155(4): A353Google Scholar
- 61.Wallin A, Sandström T, Söderberg M, et al. The effects of regular inhaled formoterol, budesonide and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1998; 158: 79–86Google Scholar
- 65.Cockroft DW, Swystun VA, Bhagat R. Interaction of inhaled β2-agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152: 1485–9Google Scholar
- 69.John M, Lim S, Seybold J, et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-α, granulocyte-macrophage colony-stimulating factor, and interferon-γ release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998; 157: 256–62PubMedGoogle Scholar
- 70.Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–42PubMedCrossRefGoogle Scholar
- 82.Edsbäcker S, Szefler SJ. Glucocorticoid pharmacokinetics: principles and clinical applications. In: Schleimer RP, Busse WW, O’Bryne PM, editors. Inhaled glucocorticoids in asthma: mechanisms and clinical actions. New York: Marcel Dekker, 1997: 381–445Google Scholar
- 84.Ryrfeldt Å, Andersson P, Edsbäcker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Europ J Resp Dis 1982; 63 Suppl. 122: 86–95Google Scholar
- 89.Dahlström K, Larsson P. Lung deposition and systemic availability of budesonide inhaled as nebulised suspension from different nebulisers [abstract]. Am J Respir Crit Care Med 1996; 153: A339Google Scholar
- 96.Anhøj J, Thorsson L, Bisgaard H. The systemic exposure of budesonide inhaled from a metal spacer is similar in young children and adults [abstract no. 2510]. Eur Respir J 1998; 12 Suppl. 28: 378sGoogle Scholar
- 101.Mendelson L, Welch M, Murphy K, et al. Greater efficacy of budesonide inhalation suspension compared to cromolyn sodium over 52 weeks in young children with persistent asthma [abstract]. Am J Respir Crit Care Med 2000 Mar; 161(3): A36Google Scholar
- 102.Zielen S, Jarisch A, Reichenbach J, et al. Budesonide nebulizing suspension is more effective than cromoglycate in early childhood asthma [poster]. American Thoracic Society International Conference Toronto 2000 7 May:A36Google Scholar
- 104.Curtis P. Comparison of prednisolone and nebulised budesonide in acute asthma in children: a pilot study [abstract]. Eur Respir J 1995 Sep; 8 Suppl. 19: 470sGoogle Scholar
- 108.Olaivar EA, Tuazon AO, Martirez T. Nebulized budesonide in the management of acute asthma [abstract]. Am J Respir Crit Care Med 1999 Mar; 159 (Pt 2 Suppl.): A142Google Scholar
- 120.Goodwin A. An uncontrolled assessment of nebulised budesonide in the treatment of acute infantile bronchiolitis. Br J Clin Res 1995; 6: 113–9Google Scholar
- 121.Jónsson B, Eriksson M, Söder O, et al. Budesonide delivered by dosimetric jet nebulization to preterm very low birth weight infants at high risk for development of chronic lung disease. Acta Paediatr (In press)Google Scholar
- 127.Zimmerman B, Tremblay D. Nebulized inhaled steroid (budesonide): prolonged high dose therapy in children less than age 5 [abstract]. J Allergy Clin Immunol 1990 Jan; 85: 258Google Scholar
- 130.Hultquist C. Nebulised budesonide in severe childhood asthma [letter]. Lancet 1989 Feb 18: 380Google Scholar
- 132.Grimfeld A, Lesbros D, Ostinelli J, et al. Long-term study of nebulised budesonide in young children with moderate to severe asthma [abstract]. EurRespir J 1994; 7 Suppl. 18: 27sGoogle Scholar
- 134.Pedersen S, Hansen OR. Dose response relationships to nebulized budesonide in children with asthma. Am J Respir Crit Care Med 1997; 155 (Pt 2): A268Google Scholar
- 139.Scott M, Ellis M, Cruz-Rivera M, et al. Improved asthma control with once-daily budesonide inhalation suspension (BIS; Pulmicort Respules™) in children <4 and ≥4 years of age [abstract no. 495]. J Allergy Clin Immunol 1999; 103: S130Google Scholar
- 140.Mendelson L, Cook D, Cruz-Rivera M. Budesonide inhalation suspension (BIS; Pulmicort Respules[™]) twice-daily in children <4 and ≥4 years of age with persistent asthma [abstract no. 496]. J Allergy Clin Immunol 1999; 103: S130Google Scholar
- 146.Mitchell CA, Alpers JH, Morton SM, et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma [abstract no. 2437]. Eur Respir J 1995; 8 Suppl. 19: 490sGoogle Scholar
- 148.O’Connor BJ, Basran GS, O’Connell F, et al. Oral steroid sparing effect of nebulized budesonide in chronic severe asthma. Am J Respir Crit Care Med 1996; 153: A341Google Scholar
- 150.Higenbottam TW, Clark RA, Luksza AR, et al. The role of nebulised budesonide in permitting a reduction in the dose of oral steroid in persistent severe asthma. Eur J Clin Res 1994; 5: 1–10Google Scholar
- 151.Maltais F, Bourbeau J, Tonnel AB, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of COPD. European Respiratory Society Annual Congress, Madrid, Spain, October 9–13, 1999: abstracts-on-disk [abstract no. 1949]Google Scholar
- 153.AstraZeneca. Pulmicort Respules (budesonide inhalation suspension) prescribing information. Astra Pharmaceuticals, LP, Wayne, Pennsylvania, USA, Aug 2000Google Scholar
- 154.Astra Pharmaceuticals. Pulmicort Respules data sheet. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: Datapharm Publications Ltd, 1999: 131–2Google Scholar
- 155.British National Formulary. No 36. London: The Pharmaceutical Press, 1999 Sep: 142Google Scholar
- 158.Mellon M, Leflein J, Walton-Bowen K, et al. The efficacy of budesonide inhalation suspension in infants and young children with persistent asthma using face masks or mouth pieces [abstract]. Ann Allergy Asthma Immunol 1999 Jan; 82: 99Google Scholar
- 160.Roberts GW, Rossi SOP. Compatibility of nebuliser solutions. Aust J Hosp Pharm 1993; 23: 35–7Google Scholar
- 161.Gronberg S, Bladh N, Magnusson P. Chemical compatibility of budesonide inhalation suspension (Pulmicort Respules[™]) with other nebulization products. Lund, Sweden. AstraZeneca R&D (Lund), 2000. (Data on file)Google Scholar
- 162.Smaldone GC, McKenzie J, Cruz-Rivera M. Effects of nebulizer volume on drug delivery: budesonide inhalation suspension. Am J Respir Crit Care Med 2000 Mar; 161 (3) Suppl: A36Google Scholar
- 168.Edmunds AT, Goldberg RS, Duper B, et al. A comparison of budesonide 800 μg and 400 μg via Turbohaler with disodium cromoglycate via Spinhaler for asthma prophylaxis in children. Br J Clin Res 1994; 5(11): 11–23Google Scholar
- 170.Verberne AA, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998; 158: 213–9Google Scholar
- 173.National Institutes of Health NH Lung and Blood Institute, World Health Organization. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Bethesda:NIH/NHLBI, 1998: Publication No. 96-3659BGoogle Scholar
- 174.Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998 Oct; 102 (Part 1): 605–9PubMedCrossRefGoogle Scholar
- 182.van Bever HP, Desager KN, Lijssens N, et al. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol 1999; 27(6): 369–75Google Scholar
- 184.Larsson L, Norjavaara E, Gerhardsson de Verdier M, et al. Adolescents with asthma treated with inhaled budesonide attain target height [abstract no. 3917]. Eur Respir J 2000; 16 Suppl. 31: 553sGoogle Scholar
- 185.Center for Disease Control and Prevention. Prevention of varicella: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Weekly Rep July 12, 1996; 45 (RR11): 1–43Google Scholar
- 186.American Academy of Pediatrics. Immunization in special clinical circumstances. In: Peter G, editor. 2000 Red book: report of the committee on infectious diseases. 25th ed. Elk Grove Village, IL: The Academy, 2000: 54–81Google Scholar